Kassandra Holzem, MD, is an assistant professor of Dermatology at the Medical College of Wisconsin.

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD

 interview highlighted the need for a delicate balance between deciding when to call for emergency care among patients in 

, as well as the need for transparency with patients.

This interview featured Kassandra Holzem, MD, assistant professor of Dermatology at the Medical College of Wisconsin, who spoke with the team at the 

2025 Society of Dermatology Physician Associates (SDPA) Fall Conference

 in San Antonio, Texas. Holzem was asked about takeaways from ‘Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic,’ and specifically about issues related to whether patients are skeptical about hospital admission if it is recommended.

“That definitely factors into it,” Holzem said. “Obviously, ERs are very busy nowadays. Frequently, patients will wait for a really long time too, especially depending on what time of day they're going or what day of the week it is…I think it's something that you just have to be open and honest with your patients about, saying, ‘Listen, I need you to go to the emergency room. You might have to wait a while, but I'm worried that this could be very severe or worrisome for you if you weren't treated in that setting.’”

Additionally, Holzem highlights concerns over cost as a factor impacting patient decisions to admit themselves to an emergency room. Nevertheless, she stressed the importance of communication with patients about risks versus benefits.

“I do think transparency is important, because I think then the patients relate better to you and understand what to expect,” Holzem explained. “...I think also, if you, as a clinician, have the opportunity to directly admit, sometimes we do. We are at institutions that are affiliated with a hospital, and so we might be able to page someone called the admitting medical officer and talk to them directly, and admit from the clinic. That's sometimes a possibility. If we do that, then they actually can bypass the ER, which is really nice. I will say, there are usually a lot of hurdles and headaches with that…but that's something to consider if you do have the ability to do so.”

To find out more on this topic, view Holzem’s full video segment posted above. For more information covered at SDPA, view the 

The quotes implemented in Holzem’s video summary were edited for clarity.

Holzem had no relevant financial disclosures of note.

Holzem K. Difficult Cases & Red Flags in Dermatology: When to Admit From the Clinic. Presented at the Society of Dermatology Physician Associates (SDPA) Fall Conference, November 5-9, San Antonio, TX.

Holzem K, Goff H. Stump the Experts. Presented at the Society of Dermatology Physician Associates (SDPA) Fall Conference, November 5-9, San Antonio, TX.

Videos

Holzem spoke in this interview about several additional highlights from her session at SDPA Fall regarding red flags in dermatology and when to admit from the clinic.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Chelsie Derman is an associate editor for 

who covers psychiatry, sleep medicine, geriatrics, migraine, and allergy. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

A meta-analysis of 79 randomized controlled trials (RCTs) found high uptake (92%) but moderate adherence and notable failure to complete outcome assessments in mental health app users, with engagement improved by reminders and human support.

“These preliminary patterns provide a useful foundation for future experimental research,” wrote study investigator Claudia Liu, PhD, from SEED Lifespan Strategic Research Centre at Deakin University, in Australia, and colleagues. “Beyond informing future app development, these findings also hold clinical relevance. Clinicians are increasingly asked to recommend or integrate apps into care, and our results suggest which features may help sustain patient engagement. Moreover, knowledge of typical adherence benchmarks can help clinicians set realistic expectations with patients and support them in maintaining app use over time.”

In the past 5 years, telehealth and digital mental health apps have been on the rise, offering convenience, cost-effectiveness, and tailored treatment. The global market for mental health apps is expected to reach > $17 billion by 2030.

Although RCTs support mental health apps for managing depression and anxiety, concerns remain about engagement and attrition.

In this study, investigators examined patterns of uptake, adherence, and attrition of 79 RCTs evaluating mental health apps for 

 and anxiety. The team leveraged studies from a 2024 review of RCTs on depression and anxiety apps, as well as conducted an updated search in Medline and PsycINFO from January 2024 to May 2025.

The RCTs included 92 app conditions and 78 control conditions. The sample included 49.4% with depression, 17.7% with general anxiety, 17.7% with mixed depression and anxiety, 6.3% with social anxiety, 3.8% with specific phobia, and 5.1% with panic disorder. App features included engagement reminders (70.7%), CBT-based (66.3%), symptom monitoring (52.2%), personalization features (39.1%), instructions for recommended use (38%), professional guidance (30.4%), and gamification elements (17.4%). Most trials (78.5%) included human contact. Control group types included waitlist (46.2%), placebo (24.4%), care as usual (17.9%), active therapy (5.1%), and other (6.4%).

The analysis demonstrated the high uptake of mental health apps (92.4%; 95% prediction interval [PI], 48.4% - 99.4%) across 56 conditions. More than half of users stayed on the app (61.8%; 95% PI, 53.2%-69.7%) from 21 conditions.

“This high uptake rate is promising, as it suggests that the vast majority of participants enrolled in these trials were willing to engage with an app,” investigators wrote.

 “However, these encouraging rates from controlled trials are unlikely to reflect real-world use because trial participants are typically more motivated than the general population. In naturalistic settings, uptake has been reported as low as 2% in some countries, underscoring the need to address barriers to digital health adoption.”

The study found users had lower attrition rates (18.6%; 95% CI, 2.4% - 68.3%). By follow-up, attribution rates increased nearly 10 points (28.4%; 95% PI, 3.0% - 83.7%). Investigators observed that study features that support accountability, including reminders and human contact, reduce dropout, while gamified elements did not improve, and might weaken, retention.

The research also showed participants assigned to app interventions tended to drop out more than participants on waitlists, based on the estimated risk ratio of 1.49, indicating a 49% higher dropout. However, the prediction interval is wide (0.34–6.48), meaning the true effect could range from substantially lower to much higher attrition, reflecting high variability across studies. When comparing the app groups to other types of control conditions, such as active controls or placebo apps, the attrition rates were not meaningfully different.

“When contextualized against other modalities, our pooled attrition estimates are comparable with those observed in traditional treatments: approximately 17% in face-to-face psychotherapy trials and 15% to 30% in pharmacotherapy trials,” investigators wrote.

 “This suggests that dropout is not unique to apps but rather reflects a broader challenge across mental health.”

Liu C, Torous J, Fuller-Tyszkiewicz M, et al. Uptake, Adherence, and Attrition in Clinical Trials of Depression and Anxiety Apps: A Systematic Review and Meta-Analysis. 

. Published online November 19, 2025. doi:10.1001/jamapsychiatry.2025.3439

The Growth of Mental Health Apps and Teletherapy: Why They’re So Popular | Jackson Health System. Jackson Health System. Published 2025. https://jacksonhealth.org/the-growth-of-mental-health-apps-and-teletherapy-why-theyre-so-popular/

Articles

A meta-analysis of 79 RCTs revealed high uptake (92%) but moderate adherence and notable attrition in mental health app users. Engagement improved with reminders and human support, while gamification did not enhance retention. The study highlighted the importance of understanding adherence benchmarks to set realistic expectations for app use in clinical settings. Despite promising uptake rates in trials, real-world adoption remains low, emphasizing the need to address barriers to digital health adoption. Attrition rates in app interventions were comparable to traditional treatments, indicating a broader challenge across mental health modalities.

A study showed that users readily adopt mental health apps, but adherence and follow-up completion lag; reminders and human support improve engagement.

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

Major Depressive Disorder

Major Depressive Disorder condition center page, resources on the topics of medical news and expert insight into depression can be found. Content includes articles, interviews, videos, podcasts, and breaking news on MDD research, treatment, and drug development.

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention 

Alex Hillenbrand is an assistant editor for 

. She earned her BA in English from Lafayette College in 2023 and went on to write for pop culture, entertainment, and sports media outlets before joining MJH Life Sciences in 2025. In her free time, Alex enjoys cooking, going on walks, and meeting new people. Contact her at mjhlifesciences.com.

Data from an analysis of 3 registries across continents show consistent maternal, neonatal, and long-term graft outcomes, confirming that 

The comparative analysis of registries from the Netherlands, Australia/New Zealand, and the United States attests to the possibility of successful post-kidney-transplantation pregnancies despite elevated risks, reaffirming the importance of close clinical surveillance of mother, fetus, and graft. Further global data harmonization is important to support clinicians managing these high-risk pregnancies.

“Pregnancy outcomes appear consistent across the registries, despite the differences in population size and methodology,” wrote study investigator Styliani Giapoutzidou, MSc, a student researcher in obstetrics and nephrology at the University of Groningen, and colleagues.

 “Pregnancy post-kidney transplant recipients are classified as high-risk. However, the risk can be moderated through advance planning and close monitoring.”

Following kidney transplantation, fertility typically returns quickly to levels sufficient for conception. Female patients are generally advised to wait ≥1 year before attempting to become pregnant. The increasing frequency of pregnancies in kidney transplant recipients calls for improved understanding among clinicians and patients and an expansive effort to collect comprehensive outcome data.

To address this gap in research, investigators reviewed data from 3 major registries.

Pregnancy After Renal Transplantation OUTcomes (PARTOUT), retrospective analysis of pregnancies 1971–2017 in the Netherlands.

The Australia and New Zealand Dialysis and Transplant Registry (ANZDATA), annual surveys of all KTR parenthood events since 1968.

The Transplant Pregnancy Registry International (TPRI), a US/international voluntary registry of pregnancies since 1991.

Investigators noted both alignment and methodological differences across PARTOUT, ANZDATA, and TPRI. Mean gestational age was approximately 35 weeks in all registries, while mean birth weight was 2383 g for PARTOUT, 2360 g (median) for ANZDATA, and 2551 g for TPRI. Regarding pregnancy outcomes, PARTOUT reports live births only after 20 weeks’ gestation, whereas ANZDATA and TPRI also include miscarriages before 20 weeks. All 3 registries define stillbirth as occurring after 20 weeks. Ectopic pregnancies are reported only by TPRI, while pregnancy terminations are reported by ANZDATA and TPRI.

Across the 3 registries, reported live birth rates ranged from 75–95%. Long-term graft outcomes were generally consistent, with graft loss occurring in 23% of PARTOUT recipients at a median of 6.44 years post-delivery, 27% of ANZDATA participants at a median follow-up of 8.08 years, and 33% of TPRI participants at a median follow-up of 14.4 years. These findings highlight the importance of ongoing post-pregnancy monitoring of kidney function in transplant recipients, even several years after delivery.

“What is the next step? Establishing global datasets with increased data acquisition should enable improved identification of predictors of pregnancy and newborn complications and should include data from populations potentially under-represented in the existing registries,” investigators concluded.

Study investigators proposed the creation of a future global dataset focused on standardising core variables, aligning definitions across registries, and securely pooling deidentified data. Collaborators would define research questions, outcomes, and analyses upfront, establish inclusive authorship, and create sustainable processes for ongoing updates. This approach aimed to strengthen evidence and improve guidance for clinicians managing high-risk pregnancies in kidney transplant recipients.

Giapoutzidou S, Hewawasam E, Gosselink ME, et al. Pregnancy after kidney transplantation: global insights based on registry data from three continents. 

. Published online November 22, 2025. doi:

https://doi.org/10.1007/s40620-025-02451-x

Pregnancy, Fertility, and Babies after a Kidney Transplant. National Kidney Foundation. Published November 8, 2024. 

https://www.kidney.org/kidney-topics/pregnancy-fertility-and-babies-after-kidney-transplant

Pregnancy after kidney transplantation is feasible with careful monitoring, as evidenced by consistent maternal, neonatal, and graft outcomes across registries from the Netherlands, Australia/New Zealand, and the United States. Despite elevated risks, successful pregnancies are possible, emphasizing the need for close clinical surveillance. Fertility typically returns quickly post-transplant, and women are advised to wait at least one year before conceiving. The study highlights the importance of global data harmonization to improve management of high-risk pregnancies and suggests creating a global dataset to standardize variables and enhance clinical guidance.

International registry analysis highlights consistent outcomes, calls for global collaboration in managing high-risk post-transplant pregnancies.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Women's Health

On the HCPLive women's health page, resources on the topics of medical news and expert insight into obstetrics, gynecology, and women's related health can be found. Content includes articles, interviews, videos, podcasts, and breaking news on women's health, and more.

Global Data Support Successful Pregnancy Outcomes in Kidney Transplant Recipients

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Martin Holst Lange, MD, PhD | Image Credit: Pharmacosmos

Amycretin has shown statistically significant weight loss and reductions in HbA1c in patients with inadequately controlled 

, according to results from a phase 2 clinical trial.

Announced by parent company Novo Nordisk on November 25, 2025, these positive headline results highlight the efficacy of the investigative unimolecular GLP-1 and amylin receptor agonist. The treatment is intended for once-weekly subcutaneous administration or once-daily oral administration.

“We are very encouraged by the phase 2 data with amycretin in people with type 2 diabetes – the first time amycretin has been evaluated in this population. The data further validate the potential best-in-class profile of amycretin,” Martin Holst Lange, MD, PhD, chief scientific officer and executive vice president of research and development at Novo Nordisk, said in a statement.

The phase 2 trial was an interventional, multinational, multi-center, randomized, double-blind, placebo-controlled, parallel, dose-finding study investigating the safety, efficacy, and pharmacokinetic properties of amycretin. Patients in the trial were required to have T2D poorly controlled (HbA1c 7-10%) and be on a stable dose of metformin with or without an SGLT2 inhibitor.

A total of 448 patients were included in the trial; of these, roughly 40% were using an SGLT2 inhibitor prior to the trial. Patients were randomly assigned among 6 subcutaneous doses from 0.4 to 40 mg weekly and 3 daily oral doses of 6 mg, 25 mg, and 50 mg, or placebo. Treatment duration was 36 weeks.

If all patients adhered to treatment from a mean baseline HbA1c of 7.8%, those taking once-weekly subcutaneous amycretin achieved dose-dependent reductions in HbA1c of ≤-1.8% by week 36. The proportion of people achieving HbA1c <7% and ≤6.5% were up to 89.1% and 76.2%, respectively. Those treated with once-daily oral amycretin achieved dose-dependent improvements up to ≤-1.5% by week 36. The proportion of patients achieving an HbA1c <7% and ≤6.5% with oral amycretin was 77.6% and 62.6%, respectively.

The placebo arm achieved HbA1c improvement of -0.2% and -0.4% with subcutaneous and oral amycretin, respectively. Additionally, estimated HbA1c improvements were statistically significant versus placebo across the board.

Additionally, patients saw statistically significant weight loss ≤-14.5% compared to -2.6% in those receiving placebo. People treated with the highest possible dose of subcutaneous amycretin were on the final maintenance dose for 4 weeks. Additionally, from a mean baseline body weight of 101.1 kg, people receiving oral amycretin also achieved substantial weight loss ≤-10.1% versus -2.5% in the placebo arm. No weight loss plateau was observed at week 36.

“Amycretin is built on the complementary biology of GLP-1 and amylin, and we are looking forward to bringing amycretin into an extensive phase 3 development program across multiple indications in 2026,” Lange said.

Novo Nordisk has also announced its plan to initiate a phase 3 development program for adults with T2D in 2026.

Novo Nordisk. Novo Nordisk phase 2 trial with amycretin reports significant weight loss and HbA1c reduction in type 2 diabetes. November 25, 2025. Accessed November 25, 2025. 

https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916463

Amycretin, a GLP-1 and amylin receptor agonist, demonstrated significant weight loss and HbA1c reduction in a phase 2 trial for type 2 diabetes patients. Conducted by Novo Nordisk, the trial involved 448 patients with inadequately controlled diabetes on metformin, with or without an SGLT2 inhibitor. Participants received varying doses of subcutaneous or oral amycretin, showing dose-dependent improvements in HbA1c and weight loss compared to placebo. Novo Nordisk plans to advance amycretin to phase 3 trials in 2026, exploring its potential across multiple indications.

The investigational unimolecular GLP-1 and amylin receptor agonist substantially improved weight loss in a phase 2 trial.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Obesity Management

Obesity Management condition center page, resources on the topics of medical news and expert insight into clinical weight management can be found. Content includes articles, interviews, videos, podcasts, and breaking news on obesity research, treatment, and drug development.

Type 2 Diabetes

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Professor Stephen Nicholls is a world-renowned cardiologist, and leads the Victorian Heart Hospital (VHH) at Monash University.

Tirzepatide Bests Dulaglutide in Cardiovascular Outcomes in HF, With Stephen Nicholls, MD

atherosclerotic cardiovascular disease (ASCVD)

 who received treatment with tirzepatide, irrespective of prior history of 

, were significantly less likely to experience death due to any cause or an HF event, compared to dulaglutide, according to a prespecified analysis of the SURPASS-CVOT trial.

American Heart Association’s Scientific Sessions 2025

 in New Orleans, Louisiana, by Stephen Nicholls, MD, PhD, director of the Monash Victorian Heart Institute in Melbourne, Australia, and professor of cardiology at Monash University.

“SURPASS-CVOT wasn’t specifically a heart failure study, but 20% of people in the trial had a prior history of heart failure,” Nicholls told 

 in an exclusive interview. “So, it becomes really important because we know there’s emerging data suggesting that the GLP-1 receptor agonists and tirzepatide have favorable effects on quality of life, 6-minute walk, and potential clinical events in patients with obesity-associated heart failure.”

SURPASS-CVOT was an event-driven, randomized, double-blind, active comparator, parallel-group study conducted at 640 sites across 30 countries. Patients were randomly assigned in a 1:1 ratio to either subcutaneous tirzepatide in doses up to 15 mg or dulaglutide 1.5 mg, once weekly. Patients were then followed for cardiovascular outcomes and other measures every 4 weeks for the first 24 weeks, and then every 3 months thereafter.

Patients eligible for inclusion were required to be ≥40 years of age, have 

 treated with either lifestyle or glucose-lowering medications, an HbA1c value ≥7% and ≤10.5% at screening, a body mass index (BMI) ≥25 kg/m2, and established ASCVD. Patients with prior pancreatitis, clinically significant gastric emptying abnormality, acute or chronic hepatitis, and other criteria were excluded.

A total of 13,299 patients were randomized during the trial, with a mean age of 64.1 +/- 8.8 years and a mean BMI of 32.6 +/- 5.5 kg/m2. Ultimately, tirzepatide demonstrated non-inferiority to dulaglutide, reducing major adverse cardiovascular events such as cardiovascular death, myocardial infarction, or 

 (HR, 0.92; 95% CI, 0.83-1.01) in adults with T2D and ASCVD.

In this prespecified analysis, Nicholls and colleagues highlighted the cardiovascular effects displayed in the trial, specifically in patients with and without a history of HF at baseline. Cardiovascular events included time to first occurrence of HF composite – consisting of HF events requiring hospitalization and all-cause or cardiovascular death – and individual outcomes of HF, as well as major adverse cardiovascular events.

Ultimately, the composite of all-cause death or HF events occurred in a substantially lower proportion of patients in the tirzepatide group (10.5% vs 12.1%; HR, 0.86; 95% CI, 0.77-0.95). Among a total of 2678 (20.3%) patients with a history of HF, more patients had a history of coronary artery disease (77.6% vs 61.8%) and prior myocardial infarction (57.8% vs 44.5%) than those without HF.

In patients with a history of HF, Nicholls and colleagues found HRs of 0.83 for all-cause death or HF events (95% CI, 0.7-0.99), 0.85 for cardiovascular death or HF events (95% CI, 0.7-1.03), 0.8 for cardiovascular death (95% CI, 0.63-1.02), and 0.97 for hospitalization or urgent visits for HF (95% CI, 0.73-1.27).

“I think the take-home message is that this is a useful therapeutic in the clinic,” Nicholls said. “It has favorable effects on a range of metabolic parameters which are superior to GLP-1 receptor agonists. It looks like it’s at least as good in terms of atherosclerotic events; if you look at heart failure events combined, there’s a more favorable effect. I think the next step is to see what that looks like in prospective trials in patients with heart failure.”

Nicholls S, D’Alessio D. Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure (pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial). Presented at the American Heart Association’s Scientific Sessions 2025. New Orleans, Louisiana. November 8-10.

Nicholls SJ, Bhatt DL, Buse JB, et al. Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics. Am Heart J. 2024;267:1-11. 

Nicholls highlights tirzepatide’s capacity to lower the risk of heart failure mortality, as well as hospitalizations or urgent visits.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Atherosclerotic Cardiovascular Disease

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Study findings suggest ChatGPT and Gemini both require further model improvements before relying solely on LLMs in clinical nutrition practice.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Irritable Bowel Syndrome

On the HCPLive irritable bowel syndrome page, resources on the topics of medical news and expert insight into IBS can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBS, IBD, and more.

AI Tools Fall Short for Dietary Recommendations for Managing IBS

Diana Isaacs, PharmD, is an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic.

Podcasts

Explore the latest findings on GLP-1 drugs, including their impact on Alzheimer's and promising results for type 1 diabetes treatment.

Dementia and Alzheimer Disease

Alzheimer Disease condition center page, resources on the topics of medical news and expert insight into Alzheimer's can be found. Content includes articles, interviews, videos, podcasts, and breaking news on dementa and Alzheimer disease research, treatment, and drug development.

Type 1 Diabetes

Diabetes Dialogue

Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives is a monthly podcast hosted by Diana Isaacs, PharmD, and Natalie Bellini, DNP, aimed at providing a regular roundup of the latest clinically applicable insights across diabetes and metabolic diseases, with a focus on leveraging technology to improve care.

podcasts page features a feed of medical news and interview podcast series, including DocTalk, Lungcast, Derm Discussions, and Heart Trials.

Diabetes Dialogue: Semaglutide Falls Short in Alzheimer Disease, Tirzepatide Shows Promise in T1D

Shannon C. Trotter, DO, is a dermatologist and podcast host from Springfield, Ohio.

This interview at the SDPA Fall Dermatology Conference highlights several topics covered in sessions presented by Trotter.

Discussing Granuloma Annulare, Lichenoid Disorders, and Social Media, With Shannon Trotter, DO

Matthew Dapas, PhD, research assistant professor at Northwestern University Feinberg School of Medicine

At ACR 2025, Dapas discusses how polygenic risk scores link genetic risk to SLICC criteria, advancing precision medicine in systemic lupus erythematosus.

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Lupus

Polygenic Risk Scores Reveal Genetic Drivers of Lupus Heterogeneity, With Matthew Dapas, PhD

IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

New Evidence on Pediatric IgAN Progression Supports Need for Extended Follow-Up

Evan Stein, MD, PhD, is the COO and CSO of LIB Therapeutics.

Stein discusses the results of a groundbreaking open-label extension, which indicates the efficacy and safety of this investigative oral PCSK9 inhibitor.

Dyslipidemia

Lerodalcibep Efficaciously Reduces LDL-C Lastingly and Long-Term, With Evan Stein, MD, PhD

Children with MASLD were more likely to live in neighborhoods with greater socioeconomic and environmental disadvantage than those with overweight or obesity but without MASLD.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Socioeconomic, Environmental Disadvantage Linked to Pediatric MASLD Risk

Two large cohort studies found greater infection and implant-related risks in patients with atopic skin conditions after major surgeries.


Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Atopic Diseases Significantly Raise the Risk of Post-Surgical Complications

Novo Nordisk has terminated the 1-year follow-up for the evoke and evoke+ trials after no significant reduction was indicated in either.

Geriatrics

Geriatric medicine condition center page is a comprehensive resource for clinical news and insights on frequent geriatric-related diseases and conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for sleep disorder, dementia, Alzheimer's disease, and more.

Semaglutide Fails to Demonstrate Reduction in Alzheimer’s Progression Versus Placebo

Sayna Norouzi, MD, is an assistant professor of medicine, clinical nephrologist, and founder and director of the glomerular disease and polycystic kidney disease clinics at Loma Linda University Medical Center.

The panel discusses how clinicians assess progression in IgA nephropathy and the importance of recognizing high-risk patients early. They emphasize that proteinuria is a central prognostic marker, and that achieving sustained reduction is critical. However, they note that ongoing eGFR decline, even when proteinuria appears improved, signals continued immune-mediated injury and should prompt re-evaluation. The group then addresses diagnostic challenges, including the fact that many patients first present after significant kidney damage has already occurred. To improve early detection, they support lowering the biopsy threshold to persistent proteinuria around 0.5 g/day, particularly when accompanied by hematuria. Increased awareness among primary care clinicians is highlighted as essential for earlier referral. Finally, the discussion includes the role of the RaDaR Registry, which collects long-term real-world data to help identify progression patterns and refine risk stratification. Overall, the segment underscores the need for early diagnosis and vigilant monitoring.

Latest News

Tips on Patient Communication in Dermatology, With Kassandra Holzem, MD

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Global Data Support Successful Pregnancy Outcomes in Kidney Transplant Recipients

Novo Nordisk’s Amycretin Demonstrates Superior Weight Loss Versus Placebo

Tirzepatide Bests Dulaglutide in Cardiovascular Outcomes in HF, With Stephen Nicholls, MD